Boronic prodrug of endoxifen as an effective hormone therapy for breast cancer
- 14 June 2015
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 152 (2) , 283-291
Abstract
As a prodrug, tamoxifen is activated by the P450 enzyme CYP2D6 that is responsible for converting it to the active metabolites, 4-hydroxytamoxifen and endoxifen. Patients with genetic polymorphisms of CYP2D6 may not receive the full benefit of tamoxifen therapy. There is increasing evidence that poor metabolizer patients have lower plasma concentrations of endoxifen and suffer worse disease outcome, although some clinical studies reported no correlation between CYP2D6 polymorphism and tamoxifen therapy outcome. Endoxifen is currently undergoing clinical trials as a potentially improved and more potent SERM (Selective Estrogen Receptor Modulator) for endocrine therapy that is independent of CYP2D6 status in patients. However, direct administration of endoxifen may present the problem of low bioavailability due to its rapid first-pass metabolism via O-glucuronidation. We have designed and synthesized ZB483, a boronic prodrug of endoxifen suitable for oral administration with greatly enhanced bioavailability by increasing the concentration of endoxifen in mouse blood. Our study demonstrated that ZB483 potently inhibited growth of ER+ breast cancer cells in vitro and was efficiently converted to endoxifen in cell culture media by oxidative deboronation. This metabolic conversion is equally efficient in vivo as indicated in the pharmacokinetic study in mice. Moreover, when administered at the same dose, oral ZB483 afforded a 30- to 40-fold higher plasma level of endoxifen in mice than oral administration of endoxifen. The significantly enhanced bioavailability of endoxifen conferred by the boronic prodrug was further validated in an in vivo efficacy study. ZB483 was demonstrated to be more efficacious than endoxifen in inhibiting xenograft tumor growth in mice at equal dosage but more so at lower dosage. Together, these preclinical studies demonstrate that ZB483 is a promising endocrine therapy agent with markedly enhanced bioavailability in systemic circulation and superior efficacy compared to endoxifen.Keywords
Funding Information
- National Institute on Minority Health and Health Disparities (2G12MD007595)
This publication has 31 references indexed in Scilit:
- Tamoxifen dose and serum concentrations of tamoxifen and six of its metabolites in routine clinical outpatient careBreast Cancer Research and Treatment, 2014
- CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-Analysis of Heterogeneous Study PopulationsClinical Pharmacology & Therapeutics, 2013
- Tamoxifen and CYP2D6: A Contradiction of DataThe Oncologist, 2012
- Pharmacological Characterization of 4-hydroxy-N-desmethyl Tamoxifen, a Novel Active Metabolite of TamoxifenBreast Cancer Research and Treatment, 2004
- Active Tamoxifen Metabolite Plasma Concentrations After Coadministration of Tamoxifen and the Selective Serotonin Reuptake Inhibitor ParoxetineJNCI: Journal of the National Cancer Institute, 2003
- Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment.1991
- DISTRIBUTION OF 4-HYDROXY-N-DESMETHYLTAMOXIFEN AND OTHER TAMOXIFEN METABOLITES IN HUMAN BIOLOGICAL-FLUIDS DURING TAMOXIFEN TREATMENT1989
- IDENTIFICATION OF 4-HYDROXY-N-DESMETHYLTAMOXIFEN AS A METABOLITE OF TAMOXIFEN IN HUMAN BILE1988
- Metabolites of tamoxifen in animals and man: Identification, pharmacology, and significanceBreast Cancer Research and Treatment, 1982
- Estrogen-receptor binding and biologic activity of tamoxifen and its metabolites.1980